|
Stages III–IV (n=41)
|
P53
| |
Phospho-p53
| |
Wip1
| |
Nuclear phospho-p38
| |
Cytoplasmic phospho-p38
| |
|---|
| |
Positive
|
Negative
| |
High
|
Low
| |
High
|
Low
| |
High
|
Low
| |
High
|
Low
| |
|---|
| |
n=14
|
n=27
|
p-value
|
n=38
|
n=3
|
p-value
|
n=5
|
n=36
|
p-value
|
n=38
|
n=3
|
p-value
|
n=30
|
n=11
|
p-value
|
|---|
|
Age ≥60
|
6 (43%)
|
8 (30%)
|
0.49
|
13 (34%)
|
1 (33%)
|
1
|
1 (20%)
|
13 (36%)
|
0.64
|
13 (34%)
|
1 (33%)
|
1
|
12 (40%)
|
2 (18%)
|
0.28
|
|
FIGO stage IV
|
5 (36%)
|
8 (30%)
|
0.73
|
13 (34%)
|
0 (0%)
|
0.54
|
2 (40%)
|
11 (31%)
|
0.64
|
13 (34%)
|
0 (0%)
|
0.54
|
7 (23%)
|
6 (55%)
|
0.073
|
|
Pure histology
|
11 (79%)
|
24 (89%)
|
0.39
|
32 (84%)
|
3 (100%)
|
1
|
5 (100%)
|
30 (83%)
|
1
|
33 (87%)
|
2 (67%)
|
0.39
|
26 (87%)
|
9 (82%)
|
0.65
|
|
Lymph node metastasis
|
5 (36%)
|
15 (56%)
|
0.33
|
20 (53%)
|
0 (0%)
|
0.23
|
2 (40%)
|
18 (50%)
|
1
|
20 (53%)
|
0 (0%)
|
0.23
|
16 (53%)
|
4 (36%)
|
0.48
|
|
Positive peritoneal cytology
|
12 (86%)
|
23 (85%)
|
1
|
32 (84%)
|
3 (100%)
|
1
|
4 (80%)
|
31 (86%)
|
0.57
|
32 (84%)
|
3 (100%)
|
1
|
26 (87%)
|
9 (82%)
|
0.65
|
|
Endometriosis present
|
5 (36%)
|
11 (41%)
|
1
|
15 (39%)
|
1 (33%)
|
1
|
3 (60%)
|
13 (36%)
|
0.36
|
16 (42%)
|
0 (0%)
|
0.27
|
11 (37%)
|
5 (45%)
|
0.72
|
|
Residual tumor present
|
5 (36%)
|
13 (48%)
|
0.52
|
15 (39%)
|
3 (100%)
|
0.077
|
2 (40%)
|
16 (44%)
|
1
|
16 (42%)
|
2 (67%)
|
0.57
|
10 (33%)
|
8 (73%)
|
0.036
|
|
Lymphadenectmy undone
|
4 (29%)
|
12 (44%)
|
0.50
|
14 (37%)
|
2 (67%)
|
0.55
|
1 (20%)
|
15 (42%)
|
0.63
|
15 (39%)
|
1 (33%)
|
1
|
10 (33%)
|
6 (55%)
|
0.29
|
- FIGO International Federation of Gynecology and Obstetrics
